Open AccessThe cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy
Author(s) -
Jason R Andrews,
Lawn Sd,
Corina Rusu,
Robin Wood,
Farzad Noubary,
Bender Ma,
C. Robert Horsburgh,
Elena Losina,
Freedberg Ka,
Rochelle P. Walensky
Publication year - 2012
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283522d47
Subject(s) - medicine , tuberculosis , sputum , antiretroviral therapy , cost effectiveness , human immunodeficiency virus (hiv) , viral load , immunology , pathology , risk analysis (engineering)
In settings with high tuberculosis (TB) prevalence, 15-30% of HIV-infected individuals initiating antiretroviral therapy (ART) have undiagnosed TB. Such patients are usually screened by symptoms and sputum smear, which have poor sensitivity.